United States · Venture startup

Who invested in Ensoma

One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$53Mraised across 1 round since 2025, from 1 source

Latest round
Venture, $53MSept 2025
Investors
3
See who backed them

The rounds

  1. Sept 2025

Founders and team

From the SEC filings it signed: 1 on the team.

  • Emile NuwaysirExecutive Officer, Directori

On the board, as filediAlbert M SeymourKouki M HarasakiKush M ParmarMark M ChinNihal SinhaPaula Soteropoulos

Everyone who backed them

Cormorant Asset ManagementPrivate equity1round
RTW Investments LLCGrowth equity1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list Ensoma as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Delos CapitalPrivate equityPer its own site
Solasta VenturesVC firmPer its own site

Quick answers about Ensoma

Who invested in Ensoma?

Ensoma's investors include Cormorant Asset Management, Catalio Capital Management and RTW Investments LLC.

How much has Ensoma raised?

Ensoma has raised $53M across 1 round since 2025.

When did Ensoma last raise?

Ensoma's most recent round was a Venture of $53M in Sept 2025.

What was Ensoma's biggest round?

Its most recent round, $53M in Sept 2025, is also its largest on record.

Who backed Ensoma first?

Ensoma's first round on record, in Sept 2025, was backed by Cormorant Asset Management, Catalio Capital Management and RTW Investments LLC.

What stage is Ensoma at?

Ensoma's latest named round is a Venture, in Sept 2025.

Where is Ensoma based?

Ensoma is based in the United States.

Companies like Ensoma

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.